TY - JOUR
T1 - Pulmonary tumor thrombotic microangiopathy
AU - pour le Grrr-OH
AU - Merad, M.
AU - Alibay, A.
AU - Ammari, S.
AU - Antoun, S.
AU - Bouguerba, A.
AU - Ayed, S.
AU - Vincent, F.
N1 - Publisher Copyright:
© 2017 SPLF
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Pulmonary tumor thrombotic microangiopathy syndrome is a rare clinicopathological entity in which tumor cell micro-emboli in the pulmonary microcirculation induced thrombotic microangiopathy. This can cause respiratory failure, and acute or sub-acute right heart failure. Histological features include micro tumor emboli in the small arteries and arterioles of the lung associated with thrombus formation and fibro-cellular and fibro-muscular intimal proliferation. The diagnosis is however extremely difficult to make before death. Thus, most of the observations reported are based on autopsy data. Very rare diagnostic observations made before death suggest the potential effectiveness of chemotherapy. Many details remain to be elucidated, interdisciplinary research is a priority with close collaboration between pathologists and clinicians to better understand this, often fatal, syndrome. It may be that the use of targeted therapies will improve the very poor prognosis allowing survival of several weeks or months after diagnosis.
AB - Pulmonary tumor thrombotic microangiopathy syndrome is a rare clinicopathological entity in which tumor cell micro-emboli in the pulmonary microcirculation induced thrombotic microangiopathy. This can cause respiratory failure, and acute or sub-acute right heart failure. Histological features include micro tumor emboli in the small arteries and arterioles of the lung associated with thrombus formation and fibro-cellular and fibro-muscular intimal proliferation. The diagnosis is however extremely difficult to make before death. Thus, most of the observations reported are based on autopsy data. Very rare diagnostic observations made before death suggest the potential effectiveness of chemotherapy. Many details remain to be elucidated, interdisciplinary research is a priority with close collaboration between pathologists and clinicians to better understand this, often fatal, syndrome. It may be that the use of targeted therapies will improve the very poor prognosis allowing survival of several weeks or months after diagnosis.
KW - Cancer
KW - Pulmonary hypertension
KW - Pulmonary tumor thrombotic microangiopathy
KW - Tumor pulmonary embolism
UR - http://www.scopus.com/inward/record.url?scp=85034415698&partnerID=8YFLogxK
U2 - 10.1016/j.rmr.2017.02.008
DO - 10.1016/j.rmr.2017.02.008
M3 - Review article
C2 - 29153757
AN - SCOPUS:85034415698
SN - 0761-8425
VL - 34
SP - 1045
EP - 1057
JO - Revue des Maladies Respiratoires
JF - Revue des Maladies Respiratoires
IS - 10
ER -